Saturday 17 October 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
80.14
2.25
−2.73%
Follow MIRM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 6 | 4 | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
7.61 | 5.83 | 6.59 | 8.47 | 0.00 | — | — | — | — |
Altman Z-Score |
4.42 | 1.85 | 0.90 | (0.26) | (0.93) | — | — | — | — |
P/FCF ratio |
132.73 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
0.54 | (0.87) | (0.23) | (3.09) | (3.32) | — | — | — | — |
P/Operating CF |
653.56 | (387.74) | (73.86) | (19.04) | (14.59) | — | — | — | — |
Beneish M-Score |
(2.46) | (2.76) | (1.69) | 0.89 | — | — | — | — | — |
P/B ratio |
12.60 | 8.71 | 4.94 | 4.59 | 4.02 | — | — | — | — |
Price to Tangible BV |
73.74 | 0.00 | 0.00 | 7.85 | 4.77 | — | — | — | — |
EV/Sales |
7.47 | 5.92 | 6.69 | 8.33 | 0.00 | — | — | — | — |
EV/EBITDA |
1,011.60 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
69.71 | 193.01 | (17.58) | (5.35) | (3.46) | — | — | — | — |
EV/FCF |
130.27 | (127.19) | (13.70) | (5.33) | (3.46) | — | — | — | — |
Quick Ratio |
2.46 | 2.83 | 4.07 | 2.71 | 3.75 | 12.56 | 8.92 | 21.22 | — |
Current Ratio |
2.67 | 3.10 | 4.45 | 2.94 | 3.91 | 12.80 | 9.13 | 21.22 | — |
Net Debt/EBITDA |
(19.11) | (0.45) | (0.21) | 0.08 | 0.14 | 1.75 | 2.07 | 2.99 | — |
Debt/Assets |
36.76% | 45.93% | 47.39% | 40.13% | 44.74% | 20.87% | 2.22% | 0.00% | 0.00% |
Debt/Equity |
0.98 | 1.37 | 1.23 | 1.00 | 1.10 | 0.29 | 0.02 | 0.00 | — |
Asset Turnover |
0.69 | 0.51 | 0.37 | 0.24 | 0.07 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
(2.39) | (0.12) | 0.43 | 0.89 | 1.58 | 0.86 | 0.75 | 0.02 | — |
Capex/Depreciation |
(0.04) | (0.83) | (1.68) | (0.09) | (31.97) | (0.36) | 140.50 | 0.00 | — |
Interest Coverage |
(1.54) | (6.12) | (7.23) | (8.21) | (9.86) | (311.33) | (24.53) | (241.75) | — |
| (8.65%) | (37.08%) | (83.65%) | (103.46%) | (57.47%) | (68.29%) | (92.98%) | (30.69%) | — | |
| (3.09%) | (13.35%) | (32.70%) | (41.90%) | (31.37%) | (53.29%) | (52.90%) | (66.76%) | — | |
ROIC |
(5.74%) | (21.61%) | (25.38%) | (62.17%) | (113.49%) | 0.00% | (201.97%) | 0.00% | — |
Return on Tangible Assets |
(6.76%) | (32.89%) | (54.26%) | (107.32%) | (67.20%) | (47.12%) | (48.81%) | (35.03%) | — |
Average Days of Receivables |
86.35 | 84.82 | 133.11 | 113.65 | 62.31 | — | — | — | — |
Research and Development Expense of Revenue |
35.71% | 41.74% | 55.06% | 138.64% | 686.74% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
49.30% | 60.03% | 78.27% | 115.58% | 309.44% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.31 | 0.37 | 0.39 | 0.17 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13.70% | 14.38% | 18.79% | 35.05% | 120.63% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.01 | (0.03) | (0.01) | (0.03) | (0.02) | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(0.60%) | (4.47%) | (13.22%) | (20.80%) | (17.37%) | — | — | — | — |
Free Cash Flow Yield |
0.75% | (0.80%) | (7.42%) | (18.46%) | (27.45%) | — | — | — | — |
Revenue per Share |
10.39 | 7.09 | 4.56 | 2.28 | 0.63 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
1.11 | 0.22 | (1.74) | (3.55) | (4.38) | (3.53) | (3.43) | (0.41) | — |
Capex per Share |
(0.02) | (0.44) | (0.49) | (0.01) | (0.63) | (0.01) | (0.02) | (8.34) | — |
Free Cash Flow per Share |
1.09 | (0.22) | (2.23) | (3.56) | (5.01) | (3.54) | (3.45) | (8.76) | — |
Cash per Share |
7.64 | 5.90 | 7.00 | 4.48 | 5.16 | 9.18 | 10.16 | 57.80 | — |
Shareholders Equity per Share |
6.27 | 4.75 | 6.08 | 4.20 | 3.96 | 6.82 | 11.35 | (19.26) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
6.27 | 4.75 | 6.08 | 4.20 | 3.96 | 6.82 | 11.35 | (19.26) | — |
Free Cash Flow |
54.87 | (10.67) | (91.05) | (120.41) | (151.78) | (89.30) | (39.64) | (7.87) | — |
Working Capital |
343.89 | 266.24 | 300.48 | 125.50 | 124.00 | 217.89 | 106.29 | 49.53 | — |
Capital Expenditures |
(0.95) | (20.99) | (20.11) | (0.28) | (19.02) | (0.22) | (0.28) | (7.50) | — |
Net Current Asset Value |
21.56 | (52.33) | (10.41) | (20.64) | (7.85) | 167.58 | 103.00 | (17.31) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.00 | 0.06 | 0.11 | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
13.95 | 22.20 | 16.92 | 3.54 | 0.61 | 0.48 | 0.00 | — | — |
Cash ROIC |
5.44% | (1.31%) | (10.82%) | (27.66%) | (37.15%) | (19.66%) | (15.84%) | (22.72%) | — |
Accounts Receivable Turnover |
5.17 | 4.61 | 4.05 | 5.65 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
8.27 | 7.41 | 5.84 | 1.39 | 0.31 | 0.19 | 0.18 | 0.00 | — |
Inventory Turnover |
4.24 | 3.65 | 3.37 | 3.50 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
35.01 | 65.35 | 57.54 | 256.33 | 1,758.06 | 1,846.09 | 3,775.05 | 0.00 | — |
Days of Inventory on Hand |
90.62 | 100.16 | 173.13 | 164.15 | 290.20 | 0.00 | 0.00 | — | — |
Average Receivables |
100.81 | 73.13 | 45.98 | 13.63 | — | — | — | — | — |
Average Payables |
12.12 | 11.02 | 8.05 | 8.93 | 6.16 | 3.25 | 1.81 | 1.81 | — |
Average Inventory |
23.65 | 22.36 | 13.94 | 3.54 | — | — | — | — | — |
Average Assets |
756.78 | 658.69 | 499.76 | 323.78 | 267.76 | 193.79 | 99.34 | 25.99 | — |
Average Common Equity |
270.17 | 237.16 | 195.35 | 131.12 | 146.15 | 151.22 | 56.52 | 56.52 | — |
Columns are period end dates